337 related articles for article (PubMed ID: 20664817)
1. Antiproliferative Properties of Type I and Type II Interferon.
Bekisz J; Baron S; Balinsky C; Morrow A; Zoon KC
Pharmaceuticals (Basel); 2010 Mar; 3(4):994-1015. PubMed ID: 20664817
[TBL] [Abstract][Full Text] [Related]
2. IRF9 is a key factor for eliciting the antiproliferative activity of IFN-alpha.
Tsuno T; Mejido J; Zhao T; Schmeisser H; Morrow A; Zoon KC
J Immunother; 2009 Oct; 32(8):803-16. PubMed ID: 19752753
[TBL] [Abstract][Full Text] [Related]
3. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7.
Sancéau J; Hiscott J; Delattre O; Wietzerbin J
Oncogene; 2000 Jul; 19(30):3372-83. PubMed ID: 10918594
[TBL] [Abstract][Full Text] [Related]
4. Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice.
Roh MR; Zheng Z; Kim HS; Jeung HC; Rha SY; Chung KY
Melanoma Res; 2013 Apr; 23(2):114-24. PubMed ID: 23358428
[TBL] [Abstract][Full Text] [Related]
5. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
Shahzadi SK; Qadir MA; Mahmood N; Ahmed M
Protein Pept Lett; 2020; 27(3):219-224. PubMed ID: 31612813
[TBL] [Abstract][Full Text] [Related]
6. Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.
Vyas K; Brassard DL; DeLorenzo MM; Sun Y; Grace MJ; Borden EC; Leaman DW
J Immunother; 2003; 26(3):202-11. PubMed ID: 12806274
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.
Nakashima H; Miyake K; Clark CR; Bekisz J; Finbloom J; Husain SR; Baron S; Puri RK; Zoon KC
Cancer Immunol Immunother; 2012 Jul; 61(7):1081-92. PubMed ID: 22159517
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of interferon-alpha therapy.
Weiss K
Semin Oncol; 1998 Feb; 25(1 Suppl 1):9-13. PubMed ID: 9482535
[TBL] [Abstract][Full Text] [Related]
9. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions.
Pfeffer LM; Wang C; Constantinescu SN; Croze E; Blatt LM; Albino AP; Nanus DM
J Urol; 1996 Nov; 156(5):1867-71. PubMed ID: 8863634
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia.
Selleri C; Sato T; Del Vecchio L; Luciano L; Barrett AJ; Rotoli B; Young NS; Maciejewski JP
Blood; 1997 Feb; 89(3):957-64. PubMed ID: 9028327
[TBL] [Abstract][Full Text] [Related]
11. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
Jonasch E; Haluska FG
Oncologist; 2001; 6(1):34-55. PubMed ID: 11161227
[TBL] [Abstract][Full Text] [Related]
12. Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness.
Fischer T; Aman J; van der Kuip H; Rudolf G; Peschel C; Aulitzky WE; Huber C
Br J Haematol; 1996 Mar; 92(3):595-603. PubMed ID: 8616023
[TBL] [Abstract][Full Text] [Related]
13. A chimeric cyclic interferon-α2b peptide induces apoptosis by sequential activation of phosphatidylinositol 3-kinase, protein kinase Cδ and p38 MAP kinase.
Blank VC; Bertucci L; Furmento VA; Peña C; Marino VJ; Roguin LP
Exp Cell Res; 2013 Jun; 319(10):1471-81. PubMed ID: 23562842
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy: the interferon-alpha experience.
Kirkwood J
Semin Oncol; 2002 Jun; 29(3 Suppl 7):18-26. PubMed ID: 12068384
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin.
Kristof AS; Marks-Konczalik J; Billings E; Moss J
J Biol Chem; 2003 Sep; 278(36):33637-44. PubMed ID: 12807916
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
[TBL] [Abstract][Full Text] [Related]
18. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor confers resistance to the antiproliferative effect of interferon-alpha.
Flowers CC; Flowers SP; Nabel GJ
Mol Med; 1998 Jun; 4(6):402-12. PubMed ID: 10780883
[TBL] [Abstract][Full Text] [Related]
19. Differential antiviral effects of pegylated interferon-α2a and pegylated interferon-α2b in chronic hepatitis C.
Durante-Mangoni E; Parrella A; Iossa D; Andini R; Molaro R; Battimelli C; Sodano G; Utili R
Clin Drug Investig; 2014 Dec; 34(12):871-8. PubMed ID: 25349040
[TBL] [Abstract][Full Text] [Related]
20. Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057.
Miles S; Levine A; Feldstein M; Carden J; Cabriallas S; Marcus S; Mitsuyasu R; Gill P
Cytokines Cell Mol Ther; 1998 Mar; 4(1):17-23. PubMed ID: 9557213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
